Compare TLX & IQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | IQ |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | Australia | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | TLX | IQ |
|---|---|---|
| Price | $7.88 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $21.13 | $2.91 |
| AVG Volume (30 Days) | 320.7K | ★ 10.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.57 |
| Revenue Next Year | N/A | $3.79 |
| P/E Ratio | $150.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $1.43 |
| 52 Week High | $19.93 | $2.76 |
| Indicator | TLX | IQ |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 25.43 |
| Support Level | $7.72 | N/A |
| Resistance Level | $8.34 | $2.16 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 94.83 | 17.59 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.